MX375514B - Proteína de fusión. - Google Patents

Proteína de fusión.

Info

Publication number
MX375514B
MX375514B MX2016003530A MX2016003530A MX375514B MX 375514 B MX375514 B MX 375514B MX 2016003530 A MX2016003530 A MX 2016003530A MX 2016003530 A MX2016003530 A MX 2016003530A MX 375514 B MX375514 B MX 375514B
Authority
MX
Mexico
Prior art keywords
fusion protein
nbp
p75ntr
pain
symptom
Prior art date
Application number
MX2016003530A
Other languages
English (en)
Other versions
MX2016003530A (es
Inventor
Simon Westbrook
Original Assignee
Levicept Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Levicept Ltd filed Critical Levicept Ltd
Publication of MX2016003530A publication Critical patent/MX2016003530A/es
Publication of MX375514B publication Critical patent/MX375514B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2807—Headache; Migraine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2842—Pain, e.g. neuropathic pain, psychogenic pain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Epidemiology (AREA)

Abstract

La presente invención se refiere a una proteína de fusión de p75NTR proteína deunión a neurotrofina (NBP)-Fc, que comprende una porción de p75NTR(NBP) y una porción de inmunoglobulina; en ciertas modalidades, la proteína de fusión p75NTR(NBP)-Fc es para uso en el tratamiento de dolor y/o un síntoma de dolor.
MX2016003530A 2013-09-18 2014-09-18 Proteína de fusión. MX375514B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1316592.3A GB201316592D0 (en) 2013-09-18 2013-09-18 Fusion protein
PCT/GB2014/052833 WO2015040398A1 (en) 2013-09-18 2014-09-18 Fusion protein

Publications (2)

Publication Number Publication Date
MX2016003530A MX2016003530A (es) 2016-10-13
MX375514B true MX375514B (es) 2025-03-06

Family

ID=49552839

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016003530A MX375514B (es) 2013-09-18 2014-09-18 Proteína de fusión.

Country Status (26)

Country Link
US (3) US9873728B2 (es)
EP (1) EP3046934B1 (es)
JP (3) JP6681834B2 (es)
KR (1) KR102205633B1 (es)
CN (1) CN105873943B (es)
AU (1) AU2014322842B2 (es)
CA (1) CA2924410C (es)
CY (1) CY1121347T1 (es)
DK (1) DK3046934T3 (es)
EA (1) EA037416B1 (es)
ES (1) ES2714694T3 (es)
GB (1) GB201316592D0 (es)
HR (1) HRP20190434T1 (es)
HU (1) HUE043273T2 (es)
IL (1) IL244588B (es)
LT (1) LT3046934T (es)
MX (1) MX375514B (es)
NZ (1) NZ718044A (es)
PL (1) PL3046934T3 (es)
PT (1) PT3046934T (es)
RS (1) RS58463B1 (es)
SG (1) SG11201602068QA (es)
SI (1) SI3046934T1 (es)
SM (1) SMT201900122T1 (es)
TR (1) TR201903490T4 (es)
WO (1) WO2015040398A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104302326B (zh) 2012-03-14 2018-03-30 利维塞普特有限公司 P75ntr神经营养因子结合蛋白的治疗性用途
GB201316592D0 (en) 2013-09-18 2013-10-30 Levicept Ltd Fusion protein
GB201412748D0 (en) 2014-07-17 2014-09-03 Levicept Ltd Therapeutic use of P75NTR neurotrophin binding protein
GB201504691D0 (en) 2015-03-19 2015-05-06 Levicept Ltd Fusion protein
EP3711772A1 (en) 2019-03-20 2020-09-23 Oslo Universitetssykehus HF Recombinant proteins and fusion proteins
CN113456799A (zh) * 2020-12-25 2021-10-01 苏州澳宗生物科技有限公司 一种p75ECD在制备用于调节疼痛的药物中的应用
CN112851794B (zh) * 2021-02-04 2023-05-23 苏州铂维生物科技有限公司 一种基于cd271的抗原表位及其应用
US11608371B1 (en) * 2021-10-21 2023-03-21 Petmedix Ltd Therapeutic molecules
WO2023067358A1 (en) * 2021-10-21 2023-04-27 Petmedix Ltd Proteins comprising the extracellular domain of p75ntr
AU2024218779A1 (en) * 2023-02-08 2025-08-28 Levicept Limited Fusion protein
WO2024165872A1 (en) * 2023-02-09 2024-08-15 Petmedix Ltd Therapeutic molecules comprising variants of the extracellular domain of p75 neurotrophin receptor (p75ntr)
GB202307936D0 (en) * 2023-05-26 2023-07-12 Levicept Ltd Fusion protein
GB202400055D0 (en) 2024-01-03 2024-02-14 Tribune Therapeutics Ab Use of ccn domain-containing proteins for the treatment of disease
WO2025181485A1 (en) 2024-02-27 2025-09-04 Levicept Limited P75 neurotrophin receptor-fc fusion protein for use in pain therapy
WO2025181486A1 (en) 2024-02-27 2025-09-04 Levicept Limited Process for manufacturing of glycosylated p75ntr-fc fusion protein

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9022648D0 (en) 1990-10-18 1990-11-28 Charing Cross Sunley Research Polypeptide and its use
FR2686900B1 (fr) * 1992-01-31 1995-07-21 Rhone Poulenc Rorer Sa Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant.
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
JP2007531707A (ja) 2003-10-15 2007-11-08 ピーディーエル バイオファーマ， インコーポレイテッド ＩＧの重鎖定常領域の位置２５０、３１４および／または４２８の変異誘発によるＦｃ融合タンパク質血清半減期の改変
US20090232808A1 (en) * 2005-01-28 2009-09-17 Apollo Life Sciences Limited Molecules and chimeric molecules thereof
JPWO2007026567A1 (ja) 2005-08-30 2009-03-05 国立大学法人 千葉大学 ｐ７５ＮＴＲ阻害剤を有効成分として含有する鎮痛剤
US20070243132A1 (en) * 2005-12-22 2007-10-18 Apollo Life Sciences Limited Transdermal delivery of pharmaceutical agents
GB0717985D0 (en) * 2007-07-20 2007-10-24 Asterion Ltd Growth hormone fusion proteins
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
US20100061981A1 (en) 2008-08-15 2010-03-11 The Salk Institute For Biological Studies p75NTR MEDIATES EPHRIN-A REVERSE SIGNALING
EP3009145A1 (en) * 2009-03-30 2016-04-20 Mount Sinai School of Medicine of New York University Influenza virus vaccines and uses thereof
WO2011047267A1 (en) * 2009-10-15 2011-04-21 Genentech, Inc. Chimeric fibroblast growth factors with altered receptor specificity
CA2782320A1 (en) * 2009-12-02 2011-06-09 Acceleron Pharma Inc. Compositions and methods for increasing serum half-life of fc fusion proteins
CN102233128B (zh) * 2010-11-26 2013-04-17 王延江 一种p75NTR-ECD在防治阿尔茨海默病药物中应用
ITRM20110024A1 (it) 2011-01-24 2012-07-25 Consiglio Nazionale Ricerche Uso di antagonisti del recettore p75ntr e/o di agonisti del recettore trka per il trattamento delle malattie infiammatorie croniche.
US20130078250A1 (en) * 2011-08-23 2013-03-28 Oliver Ast Bispecific t cell activating antigen binding molecules
TWI476001B (zh) * 2011-12-26 2015-03-11 Ind Tech Res Inst 三倍體Ｆｃ融合蛋白及其用途
CN102586313A (zh) 2012-03-05 2012-07-18 中国人民解放军第三军医大学野战外科研究所 p75NTR-ED-Fc融合蛋白的制备方法及其在损伤中枢神经再生与功能恢复中的应用
CN104302326B (zh) 2012-03-14 2018-03-30 利维塞普特有限公司 P75ntr神经营养因子结合蛋白的治疗性用途
EP2674439B1 (en) * 2012-06-13 2017-02-01 Rottapharm Biotech S.r.l. Anti-TrkA antibodies, derivatives and uses thereof
GB201316592D0 (en) * 2013-09-18 2013-10-30 Levicept Ltd Fusion protein
GB201412748D0 (en) 2014-07-17 2014-09-03 Levicept Ltd Therapeutic use of P75NTR neurotrophin binding protein
GB201504691D0 (en) * 2015-03-19 2015-05-06 Levicept Ltd Fusion protein

Also Published As

Publication number Publication date
PT3046934T (pt) 2019-03-25
SI3046934T1 (sl) 2019-04-30
SMT201900122T1 (it) 2019-05-10
RS58463B1 (sr) 2019-04-30
ES2714694T3 (es) 2019-05-29
CA2924410C (en) 2023-01-24
US20180273603A1 (en) 2018-09-27
DK3046934T3 (en) 2019-04-08
LT3046934T (lt) 2019-03-25
IL244588A0 (en) 2016-04-21
JP6681834B2 (ja) 2020-04-15
EP3046934A1 (en) 2016-07-27
JP2020062011A (ja) 2020-04-23
JP7357088B2 (ja) 2023-10-05
EA201690469A1 (ru) 2016-12-30
KR102205633B1 (ko) 2021-01-20
NZ718044A (en) 2020-07-31
JP2022068253A (ja) 2022-05-09
JP2016531590A (ja) 2016-10-13
CN105873943A (zh) 2016-08-17
PL3046934T3 (pl) 2019-05-31
US9873728B2 (en) 2018-01-23
US10988526B2 (en) 2021-04-27
WO2015040398A1 (en) 2015-03-26
EP3046934B1 (en) 2018-12-12
EA037416B1 (ru) 2021-03-25
US20160222082A1 (en) 2016-08-04
AU2014322842A1 (en) 2016-04-07
SG11201602068QA (en) 2016-04-28
KR20160058872A (ko) 2016-05-25
HUE043273T2 (hu) 2019-08-28
HRP20190434T1 (hr) 2019-04-19
CY1121347T1 (el) 2020-05-29
CN105873943B (zh) 2023-04-07
AU2014322842B2 (en) 2018-08-16
TR201903490T4 (tr) 2019-03-21
MX2016003530A (es) 2016-10-13
IL244588B (en) 2019-12-31
CA2924410A1 (en) 2015-03-26
GB201316592D0 (en) 2013-10-30
BR112016006113A2 (pt) 2017-09-26
US20210238256A1 (en) 2021-08-05

Similar Documents

Publication Publication Date Title
MX375514B (es) Proteína de fusión.
PH12014501736B1 (en) Therapeutic use of p75ntr neurotrophin binding protein
PH12020550205A1 (en) IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
MX2019008521A (es) Heterociclos triciclicos como inhibidores de la proteina bet.
IN2014DE00193A (es)
MY200609A (en) Antibodies binding to vista at acidic ph
PH12016501644B1 (en) Binding proteins and methods of use thereof
CL2015003126A1 (es) Anticuerpos modificados de unión a fcrn humano y métodos de utilización.
EA201690314A1 (ru) Анти-garp-белок и его применения
IL240606B (en) A fcrn-binding polypeptide comprising an fcrn-binding motif (bm) and various aspects related thereto
GEP20217326B (en) Constructs having a sirp-alpha domain or variant thereof
MX2016010953A (es) Proteinas de fc multimericas.
WO2017015622A3 (en) Gdf11 binding proteins and uses thereof
CL2015003174A1 (es) Anticuerpos anti-igf-1r con abolición de la unión al fcrn y su utilización en el tratamiento de enfermedades oculares vasculares
HUE036542T2 (hu) Peptidek retina neurodegeneratív betegségének topikális kezelésében történõ alkalmazásra, különösen diabeteszes retinopátia korai szakaszaiban és más olyan retinabetegségekben, amelyekben a neurodegeneráció lényeges szerepet játszik
MX389359B (es) Uso terapeutico de la proteina de union a neurotrofina p75ntr.
WO2015084883A3 (en) Compositions and methods for treating osteoarthritis
PH12016500826A1 (en) Anti-ccl17 antibodies
IL273202A (en) Human thrombin receptor binding proteins, PAR4
HK1201278A1 (en) Combination of hb-egf binding protein and egfr inhibitor

Legal Events

Date Code Title Description
FG Grant or registration